A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-14. Anything still debated is marked as such rather than presented as settled.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
== Composition and research == Because of the numerous effects claimed by traditional medicine, there has been considerable basic research to investigate the biological properties of the fruit phytochemicals. The composition of the fruits, seeds, roots, and other constituents has been analyzed, and extracts are under study. Constituents include carotenoids, polysaccharides (comprising 30% of the pulp), vitamins, fatty acids, and peptidoglycans. Various polyphenols occur in the fruit, leaves, and root bark. One monograph indicated that consuming goji for three months or longer may improve cardiometabolic risk factors in healthy Chinese adults, although there was only low-quality evidence for such effects. A limited analysis of four studies concluded that healthy Chinese adults who consumed dried goji berries, juice or capsules for 4-16 weeks had slightly lower blood triglyceride levels and higher HDL cholesterol levels.
=== Current use === In the 21st century, the high price of nickel has led to some replacement of the metal in coins around the world. Coins still made with nickel alloys include one- and two-euro coins, 5¢, 10¢, 25¢, 50¢, and $1 U.S. coins, and 20p, 50p, £1, and £2 UK coins. From 2012 on the nickel-alloy used for 5p and 10p UK coins was replaced with nickel-plated steel. This ignited a public controversy regarding the problems of people with nickel allergy.
Mitogen-activated protein kinase 1 (MAPK1) is also known as extracellular signal-regulated kinase 2 (ERK2). Two similar protein kinases with 85% sequence identity were originally called ERK1 and ERK2. They were found during a search for protein kinases that are rapidly phosphorylated after activation of cell surface tyrosine kinases such as the epidermal growth factor receptor. Phosphorylation of ERKs leads to the activation of their kinase activity. The molecular events linking cell surface receptors to activation of ERKs are complex. It was found that Ras GTP-binding proteins are involved in the activation of ERKs. Another protein kinase, Raf-1, was shown to phosphorylate a "MAP kinase-kinase", thus qualifying as a "MAP kinase kinase kinase". The MAP kinase-kinase, which activates ERK, was named "MAPK/ERK kinase" (MEK). Receptor-linked tyrosine kinases, Ras, Raf, MEK, and MAPK could be fitted into a signaling cascade linking an extracellular signal to MAPK activation. See: MAPK/ERK pathway. Transgenic gene knockout mice lacking MAPK1 have major defects in early development. Conditional deletion of Mapk1 in B cells showed a role for MAPK1 in T-cell-dependent antibody production. A dominant gain-of-function mutant of Mapk1 in transgenic mice showed a role for MAPK1 in T-cell development. Conditional inactivation of Mapk1 in neural progenitor cells of the developing cortex lead to a reduction of cortical thickness and reduced proliferation in neural progenitor cells.
Xylazine binds at a ratio of 160:0, the lowest of all α2-adrenergic receptor agonists and 1/10th of that of medetomidine and dexmedotimidine. Xylazine is less selective than the other α2-Adrenergic receptor agonists. The analgesic effect of xylazine comes from binding to receptors at the substantia gelatinosa and locus coeruleus.
Head, Children and Young People's Service, The Rathbone Society. For services to Young People. Penelope Anne Kirby. For services to Mountain Rescue in the Lake District. Henry James Kissock. Information and Communication Technology Service Delivery Manager, Police Service of Northern Ireland. For services to the community in Northern Ireland. Melissa Kose. Emerging Talent Manager, British Airways. For services to Early Careers in Aviation. Mostaque Ahmed Koyes. Director, Community Interest Luton. For services to the community in Luton, Bedfordshire. Anna Ruth Ella Lapwood. Organist. For services to Music. Harriet Hannah Laurie. Founder, TheHorseCourse. For services to Disadvantaged People in Dorset. Jayne Anne Law. Lately Head of Honours and the Kings Award for Voluntary Service, Department for Culture, Media and Sport. For Public Service. Dr. Fenella Kate Leach (Fenella Wrigley). Chief Medical Officer and Deputy Chief Executive, London Ambulance Service NHS Trust. For services to the NHS. Helen Margaret Leadbitter. For services to Young Carers. Aryeh Leaman. For services to Young People and to the community in Hendon, London Borough of Barnet. Jeremy James Lee. Chef. For services to the Food Industry. David Levy. Senior Community Outreach Adviser, Ukraine Humanitarian Taskforce, Department for Levelling Up, Housing and Communities. For services to Refugee Resettlement. Andrew Colin MacDuff Liddell. Lately Charity Lawyer, Pitlochry. For services to Theatre and the Arts in Scotland. Fiona Ann Lindop.
Sources: en.wikipedia.org
Although CLIA specifies minimum retention periods, it does not explicitly state which entity retains ownership of the specimen during retention and after the retention period. The US currently lacks well-defined federal regulations governing the ownership and use of physical human tissue specimens, their derivatives, and the biological information they contain. The current standing by bioethicists is that patients who have consented to have their diagnostic specimens collected have also abandoned them, and thus have no ownership rights. The Common Rule permits the use of biospecimens that would otherwise be discarded, provided that the donor can not be identified, though utilization of the materials for research may require Institutional review board (IRB) approval. The Association of American Medical Colleges (AAMC) has taken the stance that it "unambiguously rejects the concept that individuals retain any property interest in their excised tissues." Proponents of patient ownership rights advocate that patients must own their samples so that they can make informed decisions about how the tissues will be used, such as in bioweapons development, stem cell research, and for-profit ventures.
==== United States ==== In the United States, buprenorphine and buprenorphine with naloxone were approved for opioid use disorder by the Food and Drug Administration in October 2002. The DEA rescheduled buprenorphine from a schedule V drug to a schedule III drug just before approval. The ACSCN for buprenorphine is 9064, and being a schedule III substance, it does not have an annual manufacturing quota imposed by the DEA. The salt in use is hydrochloride, which has a free-base conversion ratio of 0.928. In the years before buprenorphine/naloxone was approved, Reckitt Benckiser had lobbied Congress to help craft the Drug Addiction Treatment Act of 2000, which gave authority to the Secretary of Health and Human Services to grant a waiver to physicians with certain training to prescribe and administer schedule III, IV, or V narcotic drugs for the treatment of addiction or detoxification. Before this law was passed, such treatment was permitted only in clinics designed specifically for drug addiction. The waiver, which can be granted after the completion of an eight-hour course, was required for outpatient treatment of opioid addiction with buprenorphine from 2000 to 2021. Initially, the number of people each approved physician could treat was limited to 10. This was eventually modified to allow approved physicians to treat up to 100 people with buprenorphine for opioid addiction in an outpatient setting. This limit was increased by the Obama administration, raising the number of patients to which doctors can prescribe to 275.
=== Ulcerative colitis === Adalimumab may be effective and well tolerated in ulcerative colitis. It was approved by the US Food and Drug Administration (FDA) for treatment of moderate to severe cases in adults.
=== Carrying of firearms on military bases === On April 2, 2026, Sec. Hegseth signed a memo allowing military personnel to carry personal firearms on military installations such as forts, camps, bases, naval yards and recruitment centers. His stated purpose was to allow personnel to defend themselves in the event of an attack and to support their second amendment rights. Supporters of the new policy, such as the family of slain Fort Hood specialist Vanessa Guillen have applauded it saying it would save lives. Concerns remain as to how the new policy will work in practice with state firearm laws, emergency response, and active threats.
Testing for CJD has historically been problematic, due to the nonspecific nature of early symptoms and difficulty in safely obtaining brain tissue for confirmation. The diagnosis may initially be suspected in a person with rapidly progressing dementia, particularly when it is also found with the characteristic medical signs and symptoms such as involuntary muscle jerking, difficulty with coordination/balance and walking, and visual disturbances. Further testing can support the diagnosis and may include:
Sources: en.wikipedia.org
=== Cell culturing === Peptide scaffolds formed from LEGO peptides have been used extensively for 3D cell culturing as they closely resemble the porosity and the structure of extra-cellular matrices. These scaffolds have also been used in cell proliferation and differentiation into desired cell types. Experimentations with rat neurons demonstrated the usefulness of LEGO peptides in cell culturing. Rat neurons that were attached to the peptides projected functional axons that followed the contours of the peptide scaffolds.
=== Benzodiazepines === Benzodiazepines are prescribed to quell panic attacks. Benzodiazepines are also prescribed in tandem with an antidepressant for the latent period of efficacy associated with many ADs for anxiety disorder. There is risk of benzodiazepine withdrawal and rebound syndrome if BZDs are rapidly discontinued. Tolerance and dependence may occur. The risk of abuse in this class of medication is smaller than in that of barbiturates. Cognitive and behavioral adverse effects are possible. Benzodiazepines include: alprazolam (Xanax), bromazepam, chlordiazepoxide (Librium), clonazepam (Klonopin), diazepam (Valium), lorazepam (Ativan), clobazam (Frisium), oxazepam, temazepam, and Triazolam.
=== Japan === As of February 2026, 94.2% of Japan's crude oil imports came from the Middle East. However, the impacts of the oil supply disruption due to the strait closure were partly mitigated by its large stockpiles. On 16 March, the Government of Japan started releasing 80 million barrels of oil, equivalent to 15 days of domestic demand, from its strategic reserves.
(See also: Al Gore and information technology) Kodak did not refuse to invest in digital cameras, but was rather a pioneer in the field, and at one point was the market leader in digital camera sales in the United States.
The primitive gut is suspended from the posterior abdominal wall by the dorsal mesentery. The gastrointestinal tract and associated dorsal mesentery are subdivided into foregut, midgut, and hindgut regions based on the respective blood supply. The foregut is supplied by the celiac trunk, the midgut is supplied by the superior mesenteric artery (SMA), and the hindgut is supplied by the inferior mesenteric artery (IMA). This division is established by the fourth week of development. After this, the midgut undergoes a period of rapid elongation, forcing it to herniate through the navel. During herniation, the midgut rotates 90° anti-clockwise around the axis of the SMA and forms the midgut loop. The cranial portion of the loop moves to the right and the caudal portion of the loop moves toward the left. This rotation occurs at about the eighth week of development. The cranial portion of the loop will develop into the jejunum and most of the ileum, while the caudal part of the loop eventually forms the terminal portion of the ileum, the ascending colon and the initial two-thirds of the transverse colon. As the foetus grows larger, the mid-gut loop is drawn back through the umbilicus and undergoes a further 180° rotation, completing a total of 270° rotation. At this point, about 10 weeks, the caecum lies close to the liver. From here it moves in a cranial to caudal direction to eventually lie in the lower right portion of the abdominal cavity.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.